Madrigal Pharmaceuticals (MDGL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the re-election of three Class I directors: Julian Baker, Daniel Brennan, and James Daly.
An advisory vote will be held to approve executive compensation.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 is on the agenda.
Approval of the 2026 Stock Plan and the 2026 Employee Stock Purchase Plan will be considered.
Other business matters may be addressed as appropriate during the meeting.
Board of directors and corporate governance
The board recommends voting in favor of all proposals presented at the annual meeting.
The meeting will be held virtually, allowing shareholders to participate online.
Executive compensation and say-on-pay
An advisory vote on executive compensation is included in the agenda, allowing shareholders to express their views.
Latest events from Madrigal Pharmaceuticals
- Q1 2026 net sales jumped 127% to $311M, with strong patient growth and pipeline expansion.MDGL
Q1 20266 May 2026 - Record sales, pipeline expansion, and strong governance drive long-term MASH leadership.MDGL
Proxy filing28 Apr 2026 - Net sales hit $958.4M in 2025, with strong growth, pipeline expansion, and global momentum.MDGL
Q4 202513 Apr 2026 - Strong U.S. growth, pipeline expansion, and global plans set stage for long-term momentum.MDGL
TD Cowen 46th Annual Health Care Conference25 Mar 2026 - Q2 launch drove $14.6M sales, strong U.S. uptake, and set stage for 2025 European entry.MDGL
Q2 20242 Feb 2026 - Early launch success and strong data position the therapy as a foundational NASH treatment.MDGL
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Strong specialty launch with rapid growth, payer access, and global expansion plans.MDGL
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Rapid launch progress, expanding coverage, and global growth plans drive future leadership.MDGL
H.C. Wainwright 8th Annual MASH Virtual Conference19 Jan 2026 - Q3 net sales hit $62.2M, >80% coverage, and $1B cash highlight a strong Rezdiffra launch.MDGL
Q3 202417 Jan 2026